The cPLS model, followed by validation in animal models, allowed the discovery of nizatidine, a histamine receptor H2 (HRH2) blocker, for treatment of fibrotic liver disease and HCC chemoprevention [21]. Here, HRH2 is linked to hepatocellular carcinoma.